Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUOQZD)

• Drug Name: Arachidonic acid Drug Info
• Synonyms: arachidonic acid; 506-32-1; arachidonate; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; Immunocytophyte; (all-Z)-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; UNII-27YG812J1I; all-cis-5,8,11,14-eicosatetraenoic acid; Arachidonic Acid, 99%; CHEMBL15594; CHEBI:15843; YZXBAPSDXZZRGB-DOFZRALJSA-N; 27YG812J1I; cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic Acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 444899
  ChEBI ID: CHEBI:15843
  CAS Number: CAS 506-32-1
  TTD Drug ID: DMUOQZD
  INTEDE Drug ID: DR0129

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Premature labour	JB00	Approved	[10]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[11]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[12]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[13]
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[15]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[3]
Estrone	DM5T6US	Menopausal and postmenopausal disorder	GA30	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[17]

Drug(s) Metabolized By Cytochrome P450 4F2 (CYP4F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[18]
Fingolimod	DM5JVAN	Primary progressive multiple sclerosis	8A40.1	Approved	[19]
Ebastine	DMQRX24	Irritable bowel syndrome	DD91.0	Phase 4	[20]
Pafuramidine	DMFKOR9	Malaria	1F40-1F45	Phase 3	[21]
Tocopherol	DMBIJZ6	Phenylketonuria	5C50.0	Phase 2	[22]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[23]

Drug(s) Metabolized By Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[24]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[25]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Diazepam	DM08E9O	Epilepsy	8A60-8A68	Approved	[24]
Dapsone	DM4LT8A	Pneumocystis pneumonia	CA40.20	Approved	[24]
Ifosfamide	DMCT3I8	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[24]
Thalidomide	DM70BU5	Multiple myeloma	2A83	Approved	[24]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[24]
Irbesartan	DMTP1DC	Hypertension	BA00-BA04	Approved	[24]
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[30]
Naproxen	DMZ5RGV	Osteoarthritis	FA00-FA05	Approved	[31]
Mesalazine	DMOL5IU	Ulcerative colitis	DD71	Approved	[32]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[33]
Bromfenac	DMKB79O	Postoperative inflammation	1A00-CA43.1	Approved	[34]
Aminosalicylic acid	DMENSL5	Inflammatory bowel disease	DD72	Approved	[35]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[36]
Piroxicam	DMTK234	Pain	MG30-MG3Z	Approved	[35]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[37]
Gamma-homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[38]

Drug(s) Metabolized By Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[25]
Dapsone	DM4LT8A	Pneumocystis pneumonia	CA40.20	Approved	[24]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[26]
Epanova	DMHEAGL	Hypertriglyceridemia	5C80.1	Approved	[27]
Gamma-homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[26]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[26]
Omega-6-FA	DMBWY8V	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[28]
Alpha-linolenic acid	DMY64HE	Discovery agent	N.A.	Investigative	[26]
Eicosadienoic acid	DMVJK9W	Discovery agent	N.A.	Investigative	[26]
Icosapentum	DMF1CM7	Discovery agent	N.A.	Investigative	[26]

Drug(s) Metabolized By Arachidonate 5-lipoxygenase (ALOX5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epanova	DMHEAGL	Hypertriglyceridemia	5C80.1	Approved	[29]
Omega-6-FA	DMBWY8V	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[3]
Prostaglandin G/H synthase 2 (COX-2)	DE492CE	PGH2_HUMAN	Substrate	[4]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[5]
Arachidonate 5-lipoxygenase (ALOX5)	DE87OZS	LOX5_HUMAN	Substrate	[6]
Arachidonate 12-lipoxygenase (ALOX12B)	DEISPU8	LX12B_HUMAN	Substrate	[7]
Arachidonate 15-lipoxygenase (ALOX15)	DEH0J8X	LOX15_HUMAN	Substrate	[8]
Cytochrome P450 4F2 (CYP4F2)	DE3GT9C	CP4F2_HUMAN	Substrate	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2391).
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [4] PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.
• [5] Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics. 2007 Feb;17(2):145-60.
• [6] A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Eur J Pharmacol. 2008 Apr 14;584(1):166-74.
• [7] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [8] Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts. Prostaglandins Other Lipid Mediat. 2013 Oct;106:8-15.
• [9] Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta. 2011 Jan;1814(1):210-22.
• [10] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [11] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [12] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [13] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [14] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [15] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [16] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [17] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [18] Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys. 2001 May 1;389(1):123-9.
• [19] CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
• [20] cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem Biophys Res Commun. 2001 Feb 2;280(4):1135-41.
• [21] Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75.
• [22] Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci. 2004 Dec;1031:13-21.
• [23] Product information - Gilenya.
• [24] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [25] Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
• [26] Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
• [27] Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
• [28] Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
• [29] Omega-3 fatty acids and inflammatory processes. Nutrients. 2010 Mar;2(3):355-74.
• [30] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [31] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [32] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [33] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [34] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [35] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [36] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [37] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [38] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.